Renowned luminaries in Personalized Medicine
Groundbreaking companies with emerging technologies
More than 1200 peers from around the globe
50 sessions in 4 parallel tracks


The field of molecular diagnostics based on gene and protein specific biomarkers has many existing and new applications, including risk assessment, screening and monitoring disease, differential diagnosis, determination of prognosis, and response to treatment. Molecular diagnostics is applied in a wide variety of different areas, such as pre-natal diagnostic, infectious disease, autoimmune disease, pharmacogenetics, neurobiology, metabolic diseases and of course oncology. Recently, the application of molecular biomarkers – be it as patient stratification, safety, drug MOA or other marker - in health care resulted in a spur of new methods and innovations. These include, but are not limited tophysicians and patients rethinking disease treatment options, new technologies such as liquid biopsy, and the development of companion diagnostics.


Laura Esserman, M.D., MBA, Director, Carol Franc Buck Breast Care Center, Professor of Surgery and Radiology, University of California, San Francisco, Associate Director, UCSF Helen Diller Family Comprehensive Cancer Center

Laura Esserman, MD, MBA, an internationally recognized breast surgeon, breast oncology specialist and visionary in personalized medicine, is revolutionizing breast cancer screening and treatment. Read Full Bio

Water Koch, Ph.D., Vice President & Head of Global Research, Roche Molecular Systems, Inc.

Dr. Koch has been in his current role of VP and Head of Global Research for Roche Molecular Systems since 2005. As a member of the Executive Leadership Team, he sits on the Life Cycle and Business Development committees, and chairs the Research Portfolio Committee. Read Full Bio


David Spetzler, MBA, Ph.D., SVP & CSO, Caris Life Sciences

Dr. Spetzler joined the Caris scientific team in August of 2009, where he currently leads the Research and Development division of Caris. His executive and scientific oversight of the R&D team is focused on the development of clinical assays Read Full Bio


Brian Wright, VP, Marketing & Commercial Operations, Paradigm Diagnostics

Brian is the Vice President of Marketing and Commercial Operations for Paradigm. Paradigm is an Ann Arbor, MI and Phoenix, AZ based molecular information company focused on utilizing next-generation sequencing technology. Read Full Bio

Timothy Yeatman, M.D., Director & President, Gibbs Cancer Center

Dr Yeatman is a practicing surgical oncologist and was recently appointed to be the Center Director of the Gibbs Cancer Center & Research Institute, Spartanburg, SC and the President and CSO of the Guardian Research Network.  Read Full Bio

Charles Chiu, M.D., Ph.D., Asst. Prof., UCSF Lab. Med. & Infec. Diseas, Director, UCSF-Abbott Viral Dx & Discovery Center

Dr. Chiu is an expert in the development and implementation of advanced genomic technologies for pathogen discovery and clinical diagnostics, including microarrays and next-generation sequencing, for a variety of blood-borne infections. Read Full Bio

Andreas Kogelnik, M.D., Ph.D., Founder & Director, Open Medicine Institute (OMI)

Andreas Kogelnik, MD, PhD is founder and Director of OMI and a practicing physician. Prior to OMI, Dr. Kogelnik founded two companies and a non-profit organization. Having received his MD from Emory University, a PhD in Bioengineering from Georgia Tech, and completing his medical residency and fellowship at Stanford. Read Full Bio

Garry Nolan, Ph.D., Professor in the Department of Microbiology and Immunology, Stanford University

Dr. Nolan is a tenured Professor in the Department of Microbiology and Immunology at Stanford University. He has published over 140 articles (biochemistry, gene cloning and characterization, virology immunology, transcriptional biology, bioinformatics, and signaling). He holds over a dozen patents in the biotechnology arena, and was honored as one of the top 25 inventors at Stanford University. Read Full Bio

Patrice Milos, Ph.D., President & CEO, Claritas Genomics

Dr. Milos, a pioneer at the interface of genomics and medicine, leads Claritas in its mission to serve children affected with complex genetic disorders by providing timely and accurate results, resolving families’ long search for answers, combining clinical expertise of the world’s best pediatric specialists with innovative platform solutions. Read Full Bio

Michael Townsend, Ph.D., Senior Scientist, Immunology, Tissue Growth and Repair Diagnostics Discovery, Genentech

Michael Townsend received his Ph.D. in Immunology from the MRC Laboratory of Molecular Biology in Cambridge, UK followed by a postdoctoral fellowship at the Harvard School of Public Health in Boston, MA. He joined Genentech in 2005 and runs a laboratory focused on disease heterogeneity research and biomarker discovery in the Rheumatology area. Read Full Bio


  • Cancer Diagnostics 
  • Applications Expansion of Non-Invasive Prenatal Dx
  • From Biomarkers to Clinical Diagnostics
  • Proteomics and Personalized Medicine: Ongoing Partnership 
  • Applications in Medicine: Rare Disease
  • Biomarkers for Autoimmune Disease
  • Noninvasive Liquid Biopsies for Cancer Patients
  • Genetics Informed Personalized Immunotherapy

    Bio-X has a limited number of seats available for members! Contact Hanwei for details.

Web Analytics